[A20-72] Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A20-35
Last updated 01.10.2020
Project no.:
A20-72
Commission:
Commission awarded on 10.08.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies
Under consideration of the data analyses subsequently submitted, now indication of a minor added benefit in the entire therapeutic indication
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-35 | Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
Federal Joint Committee (G-BA)
2020-10-01 A G-BA decision was published.